产品
编 号：F213804
分子式：C22H23F5N4O4S
分子量：534.5
分子式：C22H23F5N4O4S
分子量：534.5
产品类型
规格
价格
是否有货
结构图
CAS No: 1781834-99-8
产品详情
生物活性：
Filanesib TFA (ARRY-520 TFA) is a selective kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib TFA induces cell death by apoptosis in vitro. Filanesib TFA has potent anti-proliferative activity.
体内研究：
Filanesib TFA (20 mg/kg, 30 mg/kg; i.p.; q4dx3) has anti-tumor activitiy in vivo.Animal Model:Female nude mice, EOC mice xenograft model
Dosage:20 mg/kg, 30 mg/kg
Administration:Intraperitoneal injection, q4dx3
Result:Induced a decrease in tumor kinetics in a dose-dependent manner.
体外研究：
Filanesib TFA inhibits human KSP with an IC50 of 6 nM by a mechanism demonstrated to be uncompetitive with respect to ATP and noncompetitive with respect to tubulin.Filanesib TFA induces mitotic arrest in multiple cell lines.Filanesib TFA exhibits anti-proliferative against a broad range of human and rodent tumor cell lines.Filanesib TFA (0.001-0.1 nM; 36 hours) induces apoptosis, by a mechanism that is independent of p53 status, as defined by formation of nucleosomes and activation of caspases 3 and 7, as well as accumulation in SubG0/1 by FACS .Filanesib TFA (0.1-100 nM; 18 hours) induces the accumulation of phospho-Histone H3 (a marker of mitosis, and an indicator of mitotic arrest) in HeLa cells.Filanesib TFA (0.78-6.25 nM; 44 hours) treatment results in G2/M arrest.Filanesib TFA (10 nM; 16 hours) treatment results in the formation of monopolar spindles.Filanesib TFA potently induces cell cycle block and subsequent death in leukemic cells via the mitochondrial pathway and has potential to eradicate AML progenitor cells.Filanesib TFA (3 μM; 6-24 hours) is able to induce caspase-2 activation.Filanesib TFA (0.003-3 μM; 24-48 hours) is cytotoxic in Type II EOC cells.
Filanesib TFA (ARRY-520 TFA) is a selective kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib TFA induces cell death by apoptosis in vitro. Filanesib TFA has potent anti-proliferative activity.
体内研究：
Filanesib TFA (20 mg/kg, 30 mg/kg; i.p.; q4dx3) has anti-tumor activitiy in vivo.Animal Model:Female nude mice, EOC mice xenograft model
Dosage:20 mg/kg, 30 mg/kg
Administration:Intraperitoneal injection, q4dx3
Result:Induced a decrease in tumor kinetics in a dose-dependent manner.
体外研究：
Filanesib TFA inhibits human KSP with an IC50 of 6 nM by a mechanism demonstrated to be uncompetitive with respect to ATP and noncompetitive with respect to tubulin.Filanesib TFA induces mitotic arrest in multiple cell lines.Filanesib TFA exhibits anti-proliferative against a broad range of human and rodent tumor cell lines.Filanesib TFA (0.001-0.1 nM; 36 hours) induces apoptosis, by a mechanism that is independent of p53 status, as defined by formation of nucleosomes and activation of caspases 3 and 7, as well as accumulation in SubG0/1 by FACS .Filanesib TFA (0.1-100 nM; 18 hours) induces the accumulation of phospho-Histone H3 (a marker of mitosis, and an indicator of mitotic arrest) in HeLa cells.Filanesib TFA (0.78-6.25 nM; 44 hours) treatment results in G2/M arrest.Filanesib TFA (10 nM; 16 hours) treatment results in the formation of monopolar spindles.Filanesib TFA potently induces cell cycle block and subsequent death in leukemic cells via the mitochondrial pathway and has potential to eradicate AML progenitor cells.Filanesib TFA (3 μM; 6-24 hours) is able to induce caspase-2 activation.Filanesib TFA (0.003-3 μM; 24-48 hours) is cytotoxic in Type II EOC cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备